Red Tree Venture Capital closes inaugural fund at $272 million
Red Tree Venture Capitala West Coast-focused life sciences venture capital firm, announced the $272 million final close of its inaugural fund, Red Tree Venture Capital Fund I.
Founded in 2020 by Heath Lukatch, Ph.D. and Jennifer Cochran, Ph.D., Red Tree is a San Francisco Bay Area-based life sciences venture capital firm focused on the investment in innovation emerging from leading West Coast academic and research institutions. The group leverages relationships with leading scientists and serial entrepreneurs at leading institutions in the region to find opportunities focused on first-in-class and/or first-in-class therapies that address significant unmet needs in the fields of oncology, neurology and immunology.
Red Tree has already committed part of its new fund to investments in ten companies, each of which is at the forefront of scientific innovation in its field:
To date, Red Tree’s portfolio includes:
- Acrigen Biosciences
- Alladapt Immunotherapies
- Excellergy Therapeutics
- Magnus Medical
- Pipeline therapeutics
- Therapeutic Rondo
- Sardona Therapeutic
- Syncope Life Sciences
- Therapeutic Virsti
Krishna Polu, MD, an experienced drug developer, completes the founding team of Red Tree.